Overview

A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction

Status:
Completed

Trial end date:
2018-06-20

Target enrollment:

Participant gender:

Summary

The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.

Phase:

Phase 2

Details

Lead Sponsor:

Bayer

Treatments:

Adenosine A1 Receptor Agonists